title: Small intestinal and pancreatic microstructures are modified by an intraduodenal CCK-A receptor antagonist administration in neonatal calves.
abstract: The aim of the present study was to investigate the role of CCK on the upper gut and pancreas microstructure and on pancreatic juice secretion in neonatal calves assessed by a repetitive intraduodenal administration of FK480, a CCK-A receptor antagonist, during the first 6 days of life. The experiment was performed on 10 neonatal calves surgically fitted with a pancreatic accessory duct catheter and duodenal cannulas. Calves were sacrificed on day 7 for tissue sampling. Treatment with FK480 resulted in: reduction of preprandial pancreatic juice secretion at days 1-3, smaller size of pancreatic acini and number of cells per acinus, reduction in intestinal crypt depth (except in the duodenal bulb), numerous modifications of intestinal villi length and width, lower mitotic index of crypt cells, and increased number and size of enterocytes with 'empty vacuoles'. In conclusion, the blockade of CCK-A receptors during early life both reduced pancreatic exocrine secretion and induced complex changes in pancreatic microstructure. The influence of CCK on the upper gut microstructure in neonatal calves could be either direct via activation of CCK-A receptors located in the mucosa of the upper gut or indirect by modulation of the secretion of pancreatic juice.
authors.affiliation: Department of Histology and Embryology, Warsaw Agricultural University, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Biernat
authors.forename: R
authors.initials: R
authors.lastname: Zabielski
authors.forename: P
authors.initials: P
authors.lastname: Sysa
authors.forename: B
authors.initials: B
authors.lastname: Sosak-Swiderska
authors.forename: I
authors.initials: I
authors.lastname: Le Huërou-Luron
authors.forename: P
authors.initials: P
authors.lastname: Guilloteau
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000494:pharmacology*; D002417:Cattle; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology; D004386:Duodenum; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology*; D007421:Intestine, Small / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D010179:Pancreas / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D010189:Pancreatic Juice / Q000378:metabolism; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D014617:Vacuoles / Q000187:drug effects / Q000473:pathology
chemical_list: D001570:Benzodiazepinones; D006727:Hormone Antagonists; D007211:Indoles; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; C082966:FR 120480; D002766:Cholecystokinin